LQDA

Liquidia Corporation

Healthcare
Medical - Pharmaceuticals
$3.82B market cap

Forecast run · Oct 29, 2026Upside rank 325 of 3,186

Model Signal

ForecastQ Daily Probabilities

50.4%

49.1%

45.4%

Analyst Consensus

Recommendation2.44/5 Buy

Last price$42.65

Price target$72.36

Implied move+69.7%

Analysts9

ForecastQ Portfolios

LQDA is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.